A comparative study with depressed patients on the acceptability of placebo use
A comparative study with depressed patients on the acceptability of placebo use
复制标题
DOI：
10.1016/j.genhosppsych.2016.05.004
复制
发表时间：
2016-07-01
影响因子：
7
通讯作者：
Nitzan, Uri
中科院分区：
文献类型：
--
作者：
Feffer, Kfir;Lichtenberg, Pesach;Nitzan, Uri
目的：在重度抑郁症患者中，安慰剂应答率一直较高。尽管如此，用安慰剂治疗抑郁症仍然存在伦理争议，并且在临床环境中通常被禁止。在本研究中，我们评估了抑郁症患者使用安慰剂的可接受性。方法：96例门诊抑郁症患者与114名健康对照者相匹配。在对安慰剂效应、其在治疗抑郁症中的疗效和局限性进行了全面解释后，研究参与者完成了一份32项的自我报告问卷。这五个核心问题解决的态度和意愿的受试者接受治疗的安慰剂在clinical setting.Results：在研究组患者中，大多数（56.7%）传达同意安慰剂治疗，如果他们遭受另一次抑郁发作。研究组和对照组均表示愿意放弃知情同意权的比例很高（分别为55.6%和50%），他们不认为安慰剂治疗是一种欺骗（56%）或减少他们的自主感（56.7%）。结论：大多数抑郁症患者愿意放弃知情同意权，以接受安慰剂治疗。这些发现应该鼓励进一步研究安慰剂的使用及其在临床实践中的合法性。(C)2016 Elsevier Inc. All rights reserved.
Objective: High rates of placebo responses are consistently reported in patients with major depressive disorder. Nonetheless, treating depression with placebo is still ethically controversial and generally prohibited in the clinical setting. In the present study, we assess the acceptability of placebo usage among depressed patients.Method: Ninety-six outpatients with major depressive disorder were matched to 114 healthy controls. After a thorough explanation of the placebo effect, its efficacy and limitations in the treatment of depression, the study participants completed a 32-item self-report questionnaire. The five core questions addressed the attitude and willingness of subjects to be treated with a placebo in the clinical setting.Results: Among study group patients, the majority (56.7%) conveyed consent for placebo treatment if they were to suffer another depressive episode. Both study group and control group expressed high rates of willingness to waive their right to informed consent (55.6% and 50%, respectively), and they did not consider placebo treatment to be a deceit (56%) or to diminish their sense of autonomy (56.7%).Conclusions: Most patients with depression are willing to waive their right to informed consent in order to receive placebo treatment. These findings should encourage further studies of placebo usage and its legitimacy in clinical practice. (C) 2016 Elsevier Inc. All rights reserved.